X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/17/2864428/0/en/Clearmind-Medicine-Announces-Exclusive-Licensing-Agreement-for-Generation-3-0-Psychedelic-Compounds-for-the-Treatment-of-Mental-Disorders.html
https://www.globenewswire.com/news-release/2024/04/10/2860639/0/en/Clearmind-Medicine-Files-U-S-Patent-Application-for-Psychedelic-Based-Treatment-for-Eating-Disorders.html
https://www.globenewswire.com/news-release/2024/04/09/2859968/0/en/Clearmind-Medicine-CEO-Issues-Letter-to-Shareholders.html
https://www.globenewswire.com/news-release/2024/03/27/2853253/0/en/Clearmind-Medicine-Announces-International-Patent-Application-for-Preventing-and-Treating-Depression.html
https://www.globenewswire.com/news-release/2024/03/27/2853200/0/en/SciSparc-Clearmind-Collaboration-Evolves-with-New-International-Patent-Application-for-Preventing-and-Treating-Depression.html
https://www.globenewswire.com/news-release/2024/03/19/2848474/0/en/Breakthrough-in-Wellness-Clearmind-Medicine-s-Psychedelic-Treatment-Granted-Divisional-Patent-Approval-in-China.html
https://www.globenewswire.com//news-release/2024/03/13/2845404/0/en/Clearmind-Medicine-Obtains-Clearance-for-its-Psychedelic-Based-Alcoholism-Clinical-Trial.html
https://www.globenewswire.com//news-release/2024/03/13/2845324/0/en/Clearmind-Medicine-Received-Approval-for-a-Voluntary-Delisting-of-its-Common-Shares-From-the-Canadian-Securities-Exchange.html
https://www.globenewswire.com//news-release/2024/02/27/2835919/0/en/SciSparc-Clearmind-Partnership-Yields-Three-New-International-Patent-Applications-for-MDMA-Ibogaine-and-Ketamine-Compounds.html
https://www.globenewswire.com//news-release/2024/02/23/2834392/0/en/Clearmind-Medicine-Receives-Approval-to-Commence-its-Phase-I-IIa-Clinical-Trial-of-CMND-100-for-Alcohol-Use-Disorder.html
Market Place
Share 
